OssDsign Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

OssDsign hat ein Gesamteigenkapital von SEK224.4M und eine Gesamtverschuldung von SEK599.0K, was einen Verschuldungsgrad von 0.3% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK313.9M bzw. SEK89.5M.

Wichtige Informationen

0.3%

Verhältnis von Schulden zu Eigenkapital

SEK 599.00k

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 137.73m
Eigenkapital	SEK 224.37m
Gesamtverbindlichkeiten	SEK 89.50m
Gesamtvermögen	SEK 313.87m

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Aug 19

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Feb 23

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Jul 15

Recent updates

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

Jun 19

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

Mar 19

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Aug 19

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: OSSDDie kurzfristigen Aktiva des Unternehmens (SEK175.4M) übersteigen seine kurzfristigen Passiva (SEK32.0M).

Langfristige Verbindlichkeiten: OSSDDie kurzfristigen Vermögenswerte des Unternehmens (SEK175.4M) übersteigen seine langfristigen Verbindlichkeiten (SEK57.5M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: OSSD über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: OSSD Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 5.4% auf 0.3% zurückgegangen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: OSSD auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: OSSD über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 3.3 % pro Jahr zurückgeht

OssDsign Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Recent updates

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Consensus EPS estimates fall by 30%, revenue upgraded

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Consensus EPS estimates fall by 15%

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to kr14.00

Insufficient new directors

Consensus revenue estimates fall by 16%

Chief Executive Officer recently bought kr133k worth of stock

Chief Executive Officer recently bought kr133k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Chief Executive Officer recently bought kr124k worth of stock

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Independent Chairman of the Board recently bought kr150k worth of stock

Consensus EPS estimates increase to -kr3.00

Price target decreased to kr17.33

Chief Executive Officer recently bought kr210k worth of stock

Chief Executive Officer recently bought kr388k worth of stock

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

Chief Financial Officer recently bought kr214k worth of stock

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

Chief Financial Officer recently bought kr298k worth of stock

New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants

Consensus forecasts updated

First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020)

Consensus forecasts updated